Cerus (NASDAQ:CERS) Sets New 52-Week Low on Insider Selling

Share on StockTwits

Cerus Co. (NASDAQ:CERS) hit a new 52-week low during mid-day trading on Monday following insider selling activity. The stock traded as low as $3.95 and last traded at $3.95, with a volume of 30983 shares. The stock had previously closed at $4.09.

Specifically, SVP Carol Moore sold 30,000 shares of Cerus stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $5.33, for a total value of $159,900.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Gail Schulze sold 15,000 shares of Cerus stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $4.19, for a total value of $62,850.00. Following the completion of the transaction, the director now directly owns 40,986 shares in the company, valued at $171,731.34. The disclosure for this sale can be found here. Insiders own 7.26% of the company’s stock.

Several equities analysts have recently weighed in on CERS shares. BidaskClub lowered Cerus from a “sell” rating to a “strong sell” rating in a research note on Friday, October 25th. BTIG Research raised Cerus from a “neutral” rating to a “buy” rating and set a $7.00 price objective on the stock in a research note on Wednesday, November 13th. Zacks Investment Research raised Cerus from a “sell” rating to a “hold” rating in a research note on Monday, October 7th. ValuEngine lowered Cerus from a “buy” rating to a “hold” rating in a research note on Monday, November 4th. Finally, Stifel Nicolaus started coverage on Cerus in a research note on Tuesday, August 27th. They issued a “buy” rating and a $7.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. Cerus presently has a consensus rating of “Hold” and a consensus price target of $7.50.

The firm has a market capitalization of $543.04 million, a PE ratio of -8.73 and a beta of 1.57. The company has a debt-to-equity ratio of 0.95, a quick ratio of 2.31 and a current ratio of 2.77. The firm has a fifty day moving average of $4.29 and a 200 day moving average of $4.92.

Cerus (NASDAQ:CERS) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $18.00 million for the quarter, compared to analysts’ expectations of $17.69 million. Cerus had a negative net margin of 100.38% and a negative return on equity of 100.59%. The business’s quarterly revenue was up 16.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.11) earnings per share. Research analysts forecast that Cerus Co. will post -0.5 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the stock. Primecap Management Co. CA raised its holdings in shares of Cerus by 4.6% during the 2nd quarter. Primecap Management Co. CA now owns 11,300,000 shares of the biotechnology company’s stock valued at $63,506,000 after buying an additional 500,000 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of Cerus by 69.2% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,544,276 shares of the biotechnology company’s stock valued at $44,046,000 after buying an additional 3,494,891 shares during the period. Janney Montgomery Scott LLC raised its holdings in shares of Cerus by 8.5% during the 3rd quarter. Janney Montgomery Scott LLC now owns 54,200 shares of the biotechnology company’s stock valued at $279,000 after buying an additional 4,250 shares during the period. California Public Employees Retirement System raised its holdings in shares of Cerus by 38.9% during the 3rd quarter. California Public Employees Retirement System now owns 245,700 shares of the biotechnology company’s stock valued at $1,267,000 after buying an additional 68,872 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Cerus by 0.3% during the 2nd quarter. Vanguard Group Inc. now owns 7,006,902 shares of the biotechnology company’s stock valued at $39,378,000 after buying an additional 23,356 shares during the period. Institutional investors and hedge funds own 75.02% of the company’s stock.

Cerus Company Profile (NASDAQ:CERS)

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Featured Article: Why do commodities matter?

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.